References
- Kleihues P, Louis DN, Wiestler OD et al. WHO grading of tumours of the central nervous system. In: WHO Classification of Tumours of the Central Nervous System. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). IARC, Lyon, France 10–11 (2007).
- Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res.64(19), 6892–6899 (2004).
- Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
- Xu X, Zhao J, Xu Z et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem.279(32), 33946–33957 (2004).
- Yan H, Parsons DW, Jin G et al.IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8), 765–773 (2009).
- Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol.116(6), 597–602 (2008).
- Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol.118(4), 469–474 (2009).
- Ichimura K, Pearson DM, Kocialkowski S et al.IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol.11(4), 341–347 (2009).
- Sonoda Y, Kumabe T, Nakamura T et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci.100(10), 1996–1998 (2009).
- Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol.174(4), 1149–1153 (2009).
- Bleeker FE, Lamba S, Leenstra S et al.IDH1 mutations at residue p.R132 (IDH1[R132]) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat.30(1), 7–11 (2009).
- Kang MR, Kim MS, Oh JE et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer125(2), 353–355 (2009).
- Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med.361(11), 1058–1066 (2009).
- Wick W, Hartmann C, Engel C et al. NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol.27(35), 5874–5880 (2009).
- Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol.27(25), 4150–4154 (2009).
- Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science324(5924), 261–265 (2009).
- Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature462(7274), 739–744 (2009).
- Struys EA, Salomons GS, Achouri Y et al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am. J. Hum. Genet.76(2), 358–360 (2005).
- Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol.91(2), 233–236 (2009).
- King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene25(34), 4675–4682 (2006).